Comparative Pharmacology
Head-to-head clinical analysis: LOCHOLEST LIGHT versus QUESTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCHOLEST LIGHT versus QUESTRAN.
LOCHOLEST LIGHT vs QUESTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing their enterohepatic reabsorption and increasing hepatic LDL receptor activity and cholesterol catabolism.
LOCHOLEST LIGHT is not a recognized drug name. No data available.
Questran (cholestyramine) is administered orally. The typical adult dose is 4 grams (one packet or one level scoop) once or twice daily, with a maximum of 24 grams per day. The powder should be mixed with at least 120 mL of fluid (e.g., water, juice).
None Documented
None Documented
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Not applicable; the drug is not absorbed and does not have a systemic half-life. Clinical effect persists as long as the resin remains in the gut (approximately 6-8 hours per dose).
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Cholestyramine is not absorbed from the gastrointestinal tract; therefore, it is excreted entirely in the feces as the intact resin, with no renal or biliary excretion.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant